Bipolar disorder (BPD) is a debilitating psychiatric illness that is increasingly considered to be a spectrum disorder. Patients experience symptoms ranging in severity from subthreshold hypomanic and depressive symptoms to severe manic and major depressive episodes. Patients with BPD often require chronic treatment. Polypharmacy—consisting of agents that exert antidepressant and antimanic effects—is common, although treatment is highly individualized, requiring physicians to try multiple medications (or combinations of medications) before identifying an effective treatment.
- What patient share do key therapies garner by line of therapy in newly diagnosed BPD patients? What are the quarterly trends in prescribing among recently-treated and newly diagnosed BPD patients?
- To what extent have newer-to-market agents (example: Allergan’s Vraylar [cariprazine], Lundbeck/Otsuka’s Rexulti [brexpiprazole], and Lundbeck/Takeda’s Trintellix [vortioxetine]) been integrated into the treatment algorithm for BPD? Where in the treatment algorithm is aripiprazole (Otsuka’s Abilify, generics) used now that it is widely generically available?
- What proportion of BPD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of drug-treated BPD patients progress to later lines of therapy within one year of diagnosis?
- What percentage of BPD patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with BPD?
Treatment Algorithms: Claims Data Analysis: Provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.
- Bipolar Disorder - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms Claims Data Analysis (US)
- Treatment Algorithms - Claims Data Analysis - Bipolar Disorder US Analysis [September 2017]
Author(s): Bethany A. Kiernan, PhD
Bethany A. Kiernan, Ph.D., is a senior director in the central nervous system/ophthalmology disorders unit of Decision Resources Group. While at Decision Resources Group, Dr. Kiernan has covered the market dynamics of numerous indications, including schizophrenia, depression, migraine, multiple sclerosis, epilepsy, and other disorders.
Dr. Kiernan’s previous experience includes eight years of scientific research conducted at Tufts University School of Medicine, Case Western Reserve University, and the College of the Holy Cross. Dr. Kiernan earned her Ph.D. degree from Case Western Reserve University.